Clinician and scientist investigators are engaged in groundbreaking myasthenia research all over the world. MGFA funds promising research studies and clinical trials to discover potential new treatments and methods of living a better quality of life with MG.
The Myasthenia Gravis Foundation of America (MGFA) requests submission of proposals to support high-impact clinical research and scientific pilot studies that are focused and innovative. High-impact clinical research proposals should focus on patient outcome measurements or advancements in clinical or research practices which improve present treatment paradigms. Scientific pilot projects will require a clear plan that will lead to new federal, pharmaceutical, or private foundation supported investigations, as well as a clear plan of how success will be assessed. The proposal should be within the scope of the MGFA’s research agenda.
Proposals for the 2024 MGFA High-Impact Pilot Project Award are now being accepted. If you are conducting research that will ultimately improve the lives of people with myasthenia gravis and related neuromuscular junction disorders, you are invited to submit a letter of intent via ProposalCentral by February 16.
The RFA is open to established and new investigators. Applications in all areas of MG research will be accepted from U.S. and international principal investigators with faculty status. Applications are not open to for-profit or small business submissions.
MGFA will fund highly meritorious projects with a maximum of $110,000, over two years, of which no more than $10,000 may be allocated to indirect costs. Funds will be expended over two years from the time of the award. Special funding requests and/or changes to the award period must be approved prior to submission of proposal through the Letter of Intent.